Recent Blog Articles
HIV rates rising: Could new forms of PrEP help?
Careful! Scary health news can be harmful to your health
Post-pandemic weight loss: There’s an app for that
Cognitive behavioral therapy for insomnia by telemedicine: Is it as good as in-person treatment?
Prediabetes diagnosis as an older adult: What does it really mean?
Is blood sugar monitoring without diabetes worthwhile?
Large review study finds low risk of erectile dysfunction after prostate biopsy
Does exercise help protect against severe COVID-19?
A new Alzheimer’s drug has been approved. But should you take it?
Need physical therapy? 3 key questions your PT will ask
Zev Schuman-Olivier, MD
Dr. Schuman-Olivier is the Medical Director, Addictions, Cambridge Health Alliance. He is also an Instructor in Psychiatry, Harvard Medical School and a board-certified addiction psychiatrist with expertise in opioid use disorder treatment and substance abuse treatment for people with co-occurring disorders. After graduating from Tufts University School of Medicine, he completed psychiatry residency at Harvard Medical School (HMS)/Cambridge Health Alliance (CHA), and the HMS addiction psychiatry fellowship. He trained at the Massachusetts General Hospital (MGH) Addiction Recovery Management Service, specializing in addiction treatment with young adults. He is a member of the Massachusetts Medical Society opioids task force. He received the American Academy of Addiction Psychiatry Young Investigator Award for research on buprenorphine diversion. He is funded through the NIH Science of Behavior Change Initiative to investigate how mindfulness influences self-regulation and medical regimen adherence. With NIDA funding through the Center for Technology and Behavioral Health (www.c4tbh.org) at Dartmouth, he has been developing MySafeRx, an integrated mobile platform for enhancing buprenorphine adherence and diversion prevention among young adults with opioid use disorders. He is on the Board of Directors of the 501(c)3 scientific non-profit organization, MySafeRx, Inc., which aims to develop, evaluate, implement and disseminate technology-based solutions to adherence in mental health and addiction treatment.